The state and industrial policy in Ireland: a case study of the Irish pharmaceutical sector

There is renewed interest in the state's role in the economic sphere but a lack of research on the viability and employment effects of alternative economic models, in particular from a ‘liberal market economy’ perspective. This article addresses this gap in the human resource management literature by undertaking a detailed case study of industrial policy in the Irish pharmaceutical sector. The proactive and resource-intensive industrial policy adopted by the Irish government and development agencies is found to have underpinned a significant strategic upgrading in this sector of the Irish economy. In turn this has facilitated the growth of high-wage, high-skill jobs. The findings highlight the potential for an active industrial policy to promote employment upgrading in liberal market economies.

Static and dynamic impacts of MERCOSUR: the case of the pharmaceutical sector

Includes bibliography

Report of the ECLAC/CCST workshop on the pharmaceutical sector in the Caribbean, 14-19 March 1986, Havana, Cuba

Presenta las recomendaciones de la reunion en la que se trato el rol del CCCT en la promocion del intercambio de informacion, el estrechamiento de la asistencia tecnica entre los paises de la region, y el de aunar los esfuerzos de los cientificos en la busqueda de soluciones a los problemas comunes en el sector farmaceutico.

Faces of pricing and profit planning at the doorstep of the EU: government pricing policy in the innovative pharmaceutical sector in Turkey

The majority of research on the pharmaceutical sector has focused on an overall micro economic, medical oriented welfare issues, whereas the marketing management role of the innovative drug manufacturer has to a large extent been disregarded. Using the case of Turkey, through a series of in-depth interviews with highly innovative companies, other marketing management possibilities to develop pricing strategies and plan for profit are explored based on broader definitions of value and transparency. Our results suggest that pharmaceutical companies as well as governments might have a too narrow focus of value and underestimate the potential long term benefits of a broader approach to marketing management and long term relationships between the various stakeholders.

Faces of pricing and profit planning in innovation at the doorstep of the EU:government pricing policy in the pharmaceutical sector in Turkey

The majority of research on the pharmaceutical sector has focused on an overall micro economic, medical oriented welfare issues, whereas the marketing management role of the innovative drug manufacturer has to a large extent been disregarded. Using the case of Turkey, through a series of in-depth interviews with highly innovative companies, other marketing management possibilities are explored based on broader definitions of value and transparency. Our results suggest that pharmaceutical companies as well as the government might have a too narrow focus of value and underestimate the potential long term benefits of a broader approach to marketing management and long term relationships between the various stakeholders.

Direction of outward FDI of EMNEs:evidence from the Indian pharmaceutical sector

This article seeks to add to the small but growing literature of emerging-market multinational enterprises (EMNEs). Using two linked large firm-level databases, it seeks to explore the determinants of outward investment of Indian pharmaceutical companies, distinguishing between developed- versus developing-country destinations. It specifically examines the impact of two firm-level characteristics that embody “non-OLI” [ownership, location, and internalization] firm-specific capabilities of EMNEs. The finding of this study is that family firms are keen on investing in other developing countries but much less so in developed countries. However, international linkages in the form of foreign investors offset this.

Análisis financiero de la empresa Novartis de Colombia y el sector farmacéutico en Colombia

El siguiente trabajo de grado para la Facultad de Administración de la Universidad del Rosario, tiene como principal objetivo realizar un análisis financiero de Novartis de Colombia, empresa multinacional Suiza que opera en Colombia como filial. Así mismo, poder indagar qué implicaciones tienen los cambios dentro del sector farmacéutico de Colombia en las finanzas de la empresa. El trabajo busca determinar de qué manera Novartis de Colombia usa sus recursos para ser una de las empresas del sector mejor posicionada a pesar de los grandes cambios que la industria farmacéutica ha estado afrontando durante los últimos años. Para esto se deben utilizar diferentes herramientas e indicadores financieros que ayudarán a identificar, analizar, describir y evaluar los aspectos claves que garantizan el éxito de la empresa.

Perfil Logístico de Colombia - Sector Farmacéutico

Hoy en día, la competitividad del sector logístico de un país constituye una de las bases para capitalizar las nuevas oportunidades de negocio que actualmente ofrecen los mercados internacionales. Sin embargo, la compleja infraestructura de Colombia sumado a las extensas cadenas de suministro de algunos de los principales sectores que conforman la economía nacional, no solo han afectado el desempeño del sector logístico colombiano, sino también han impedido que numerosas empresas colombianas logren aprovechar los 13 acuerdos comerciales vigentes entre Colombia y más de 50 países del continente americano y europeo. Este es el caso del sector farmacéutico colombiano, donde la complejidad del sector logístico nacional ha impedido en algunos casos, cumplir con los requerimientos del cliente, optimizar los tiempos de respuesta y disminuir los costos de distribución demandados por la industria. En este contexto, la investigación que nos compete describe de manera inicial y a través de indicadores macroeconómicos, la realidad del sector farmacéutico a nivel nacional e internacional. Posteriormente, los indicadores de productividad y competitividad de la industria farmacéutica nacional son abordados mediante el análisis de todas las actividades demandadas por cada uno de los eslabones que conforman la cadena de suministros del sector. Adicionalmente, el estudio comprende las problemáticas actuales del sector farmacéutico nacional y un caso de estudio relacionado con los costos que demandaría la exportación de un producto farmacéutico hacia el mercado internacional. Finalmente, mediante la opinión directa de 20 laboratorios farmacéuticos nacionales e internacionales, la presente investigación le brinda al lector un acercamiento hacia la realidad que atraviesa la industria farmacéutica colombiana en cuanto a la competitividad de sus procesos logísticos.

Análisis de los componentes de la cadena de suministro y su relación con el desempeño superior de la organización en el sector manufacturero

En este documento se evidencia como el desempeño organizacional de una empresa, entendido como el rendimiento superior de la misma, se ve modificado por las prácticas o metodologías utilizadas, aplicadas e integradas a cada uno de los componentes de la Cadena de suministros. Es así que el propósito principal es demostrar cual es la relación entre los componentes de la Cadena de Suministros y su gestión sobre los rendimientos económicos de la empresa. De esa manera se encontraron múltiples actividades que toman lugar en los procesos característicos de cada uno de los componentes de la cadena de suministros y que al final nos presentan una variabilidad sobre los rendimientos de la empresa. Cabe recalcar que la investigación se realizó con respecto a empresas pertenecientes al sector manufacturero y abarca una buena parte de este. La importancia que tiene la investigación, es el haber entregado como resultado, el conocimiento sobre algunas de las practicas más utilizadas en el sector en cada uno de sus componentes, lo cual hace de la Cadena de suministros, un factor por excelencia para ser tratado e implementado con el fin de alcanzar mayores rendimientos económicos a nivel de empresa. En la investigación se utilizaron los casos de empresas reales tanto nacionales como internacionales y se encontraron situaciones claves que evidenciaban la hipótesis de la relación entre la cadena de suministros y el desempeño organizacional. Es por ello, que si bien es ahora cierto, que las actividades desarrolladas en los componentes de la Cadena de Suministros de las empresas influyen en el incremento de los rendimientos, es importante que las empresas conozcan de esta información para tener una idea de cómo desarrollar ventajas competitivas que los posicionen como empresa y les genere entonces mayores rendimientos, o por el contrario, les genere ahorros en costos y por ende altos beneficios y nuevas inversiones en prácticas que a la larga volverá a la empresa en un organismo eficientes y próspero.

Pharmaceutical patent bargains: the Brazilian experience

In the backdrop of the strict patent regime flatly adopted by the World Trade Organization (WTO) for all countries, a few countries constantly challenge this system through aggressive patent bargains. Within the pharmaceutical sector, noticeably, some countries now threaten to issue or otherwise actually issue compulsory licenses that may sway large pharmaceutical companies into selling drugs with large discounts or into granting voluntary licenses domestically. That is conspicuously the negotiation strategy adopted by Brazil in its negotiations with big international pharmaceutical companies.This paper explains Brazil’s aggressive bargaining approach based on an analysis of two aspects of its political economy. The first has to do with the international context of patent bargaining in the post-WTO era. Accordingly, the existence of large and fast growing domestic markets position countries such as Brazil as strategic destinations for Foreign Direct Investment (FDI) and trade. Together with an absence of a propensity to innovate in pharmaceutical products, these conditions boost Brazil’s bargaining power for issuing compulsory licenses over pharmaceutical products. The second aspect is related to political economy dynamics inside Brazil. Accordingly, the political framework in Brazil undermines long-term policies and favors short-sighted ones also vis-a-vis R&D investments in the pharmaceutical industry. This remains true regardless of the strictness of the patent regime in place. The lesson of Brazil is relevant arguably for other more powerful developing countries which presently examine Brazil's approach while further challenging the WTO's strict patent policy for the future.

Patenting Strategies of the EU Pharmaceutical Industry -Crossroad between Patent Law and Competition Policy. Research Papers in Law, 1/2011

From the Introduction. The pharmaceutical sector inquiry carried out by the European Commission in 2008 provides a useful framework for assessing the relationship between the patent system on the one hand and competition policy and law on the other hand. The pharmaceutical market is not only specifically regulated. It is also influenced by the special characteristics of the patent system which enables pharmaceutical companies engaged in research activities to enter into additional arrangements to cope with the competitive pressures of early patent application and the delays in drug approval. Patents appear difficult to reconcile with the need for sufficient and adequate access to medicines, which is why competition expectations imposed on the pharmaceutical sector are very high. The patent system and competition law are interacting components of the market, into which they must both be integrated. This can result in competition law taking a very strict view on the pharmaceutical industry by establishing strict functional performance standards for the reliance on intellectual property rights protection granted by patent law. This is in particular because in this sector the potential welfare losses are not likely to be of only monetary nature. In brief, the more inefficiencies the patent system produces, the greater the risk of an expansive application of competition law in this field. The aim of the present study is to offer a critical and objective view on the use or abuse of patents and defensive strategies in the pharmaceutical industry. It shall also seek to establish whether patents as presently regulated offer an appropriate degree of protection of intellectual property held by the economic operators in the pharmaceutical sector and whether there is a need or, for that matter, scope for improvement. A useful starting point for the present study is provided by the pharmaceutical sector competition inquiry (hereafter “the sector inquiry”) carried out by the European Commission during the first half of 2008. On 8 July 2008, the Commission adopted its Final Report pursuant to Article 17 of Regulation 1/2003 EC, revealing a series of “antitrust shortcomings” that would require further investigation1.

The European Pharmaceutical Industry in a Global Economy: what drives EU exports of pharmaceuticals?. Bruges European Economic Research Papers (BEER) 31/2015.

The pharmaceutical industry is one of the most competitive sectors in the European Union. With its substantial investments in research and development, this industry represents a key asset for the European economy and a major source of growth and employment. However, despite the importance of the pharmaceutical sector for the European Union, few researchers have attempted to assess the determinants of the EU exports of pharmaceuticals. This paper aims at filling the aforementioned gap by examining what drives EU exports of pharmaceuticals. In order to tackle this question, this paper has derived hypotheses from the Gravity Model of Trade and the relevant academic literature on pharmaceuticals. Based on an econometric analysis, the research sheds light on the complex interaction of factors influencing the EU exports of pharmaceuticals. The paper finds that the protection of intellectual property in the receiving countries, their economic size, the importance of their health sector, and the quality of infrastructures constitute major drivers to the EU exports of pharmaceuticals. On the contrary, the research shows that transports costs as well as tariff barriers and non-tariff barriers tend to hinder the EU exports of pharmaceuticals.

Enhancing Knowledge Acquisition in Pharmaceutical Organisations based in Pakistan

Absorptive Capacity (ACAP) depicts the sequential order of activities connecting externally generated knowledge into an organisation; this involves a company’s ability to acquire new knowledge from an external source, assimilate and transform it, and eventually exploit it via its industrial processes and products/services. The sandwiched role of middle managers, being interlinked between decision makers and employees, has been argued as vital to organisational success. However, their role is often viewed as having conflicts astride management i.e. between employees and decision makers. This study, using a thematic analysis approach, explores and identifies the common and conflicting role of middle managers, as viewed by different respondents in organisational hierarchies. Results, based on a sample of 33 employees operating in the Pakistan Pharmaceutical sector, indicate that conflicting roles of middle managers also persist with more common roles in organisations.

Perceções de (In)Justiça na Avaliação de Desempenho das Forças de Venda: estudo em empresas do sector farmacêutico

Num mundo competitivo com alterações profundas nos processos de trabalho e desempenho, surgem necessidades de novas formas de avaliação e competências profissionais. Estas necessidades promovem um ambiente nem sempre justo e saudável, algo imprescindível para o bem-estar de uma organização. O presente estudo objetiva verificar perceções de justiça organizacional da avaliação de desempenho de duas empresas do sector farmacêutico (empresa A e empresa B). Do mesmo modo verifica-se de que forma as variáveis sociodemográficas afetam ou fragmentam a avaliação de desempenho. Este tema é pouco explorado em Portugal, contribuindo para o aprofundamento da compreensão da multidimensionalidade da perceção de justiça nas forças de vendas destas organizações. A pesquisa descritiva foi realizada por meio de levantamento, com assertivas extraídas da pesquisa de Sotomayor (2006), para investigar as perceções de justiça distributiva, processual, interpessoal e informacional. Os resultados obtidos neste estudo indicam perceção de justiça organizacional na avaliação de desempenho por parte da força de vendas em todas as quatro dimensões distintas, apresentando a justiça procedimental um score de destaque, seguida da justiça distributiva. A organização B apresenta níveis mais elevados de prevalência de justiça distributiva, procedimental, interpessoal e informacional face à organização A. No que respeita à relação entre as variáveis sociodemográficas e à perceção de justiça na avaliação de desempenho, a mesma não é suportada nesta amostra não comprometendo a perceção de justiça. Do presente estudo retira-se o quanto determinante nas organizações que envolvem forças de venda são as políticas e práticas de gestão de desempenho, acautelando o sucesso estratégico sustentado da organização, percecionando que com estas a organização as valoriza e cuida do seu bem-estar, com perceções positivas de justiça na avaliação de desempenho. / In a competitive world with profound changes in work processes and performance needs arise new forms of evaluation and professional skills. These needs foster an environment not always fair and healthy, something essential for the well-being of an organization. This study aims to verify perception of organizational justice evaluation of performance of two companies in the pharmaceutical sector (company A and company B). Likewise there is how sociodemographic varia-bles affect or fragmenting the performance appraisal. This theme is underexplored in Portugal, contributing to the deepening of understanding of the multidimensionality of perception of justice in these organizations sales forces. The descriptive research was conducted through survey, with the extracted assertions Sotomayor research (2006), to investigate the perceptions of distributive, procedural, interpersonal and informational justice. The results of this study indicate organizational justice perception on performance appraisal by the sales force in all four different dimensions, presenting procedural justice an outstanding score, followed by distributive justice. The organization B has higher levels of prevalence of distributive justice, procedural, interpersonal and informational face the organization A. As regards the relationship between sociodemographic variables and the perception of justice in performance appraisal, it is not supported in this sample does not compromising the perception of justice. The present study withdraws how decisive in organizations involving sales force policies and performance management practices, cautioning sustained strategic success of the organization, perceived that the organization values and cares for your well-being, with positive perceptions justice in performance appraisal.